CBD for Individuals with Mild Cognitive Impairment and at Risk for Alzheimer's Disease
Primary Objective
Our study is seeking individuals aged 55-85, who have been diagnosed with Mild Cognitive Impairment (MCI) and are at risk for Alzheimer's Disease. The goal of the study is to see whether cannabinoids (CBD) can improve MCI symptoms. Study medication is provided.
Description
This study plans to learn more about different types of CBD in reducing symptoms of MCI (sleep and cognitive dysfunction, anxiety, and inflammation).
Main Procedures Involved: Blood draws, questionnaires, and cognitive tests.
Duration of Participation: 24 weeks
Details
55 to 85 years
- Must be between the ages of 55 – 85. - Participant must have a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation. - Must have an informant that will be utilized over the course of the 24 week study... - Must be interested in using CBD to help with cognitive function. - Must plan on living in the Denver metro area over the next 6 months. - Able to attend in-person visits at the study site.
MoreProvided
Locations
CU Anschutz non-hospital research facilities
Principal Investigator
Kent Hutchison
Resources
Study ID
Protocol Number: 23-0619
More information available at ClinicalTrials.gov: NCT05822362
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers